A detailed history of Polar Capital Holdings PLC transactions in Cerus Corp stock. As of the latest transaction made, Polar Capital Holdings PLC holds 13,540 shares of CERS stock, worth $21,393. This represents 0.0% of its overall portfolio holdings.

Number of Shares
13,540
Previous 26,540 48.98%
Holding current value
$21,393
Previous $46,000 50.0%
% of portfolio
0.0%
Previous 0.0%

Shares

12 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2024

Nov 14, 2024

SELL
$1.7 - $2.39 $22,100 - $31,070
-13,000 Reduced 48.98%
13,540 $23,000
Q4 2023

Feb 14, 2024

SELL
$1.25 - $2.35 $25,568 - $48,069
-20,455 Reduced 43.53%
26,540 $57,000
Q3 2023

Nov 14, 2023

SELL
$1.5 - $3.07 $1.84 Million - $3.78 Million
-1,229,786 Reduced 96.32%
46,995 $76,000
Q2 2023

Dec 13, 2023

SELL
$1.79 - $2.9 $1.9 Million - $3.08 Million
-1,061,361 Reduced 45.39%
1,276,781 $3.14 Million
Q2 2023

Aug 14, 2023

SELL
$1.79 - $2.9 $1.9 Million - $3.08 Million
-1,061,361 Reduced 45.39%
1,276,781 $3.14 Million
Q1 2023

Dec 13, 2023

BUY
$2.65 - $3.81 $6.07 Million - $8.73 Million
2,291,147 Added 4875.3%
2,338,142 $6.94 Million
Q1 2023

May 15, 2023

BUY
$2.65 - $3.81 $807,735 - $1.16 Million
304,806 Added 14.99%
2,338,142 $6.94 Million
Q3 2022

Nov 14, 2022

BUY
$3.43 - $5.83 $556,846 - $946,477
162,346 Added 8.68%
2,033,336 $7.32 Million
Q2 2022

Aug 15, 2022

SELL
$4.41 - $5.69 $702,720 - $906,684
-159,347 Reduced 7.85%
1,870,990 $9.9 Million
Q1 2022

May 16, 2022

BUY
$4.81 - $6.99 $197,873 - $287,554
41,138 Added 2.07%
2,030,337 $11.1 Million
Q3 2021

Nov 15, 2021

BUY
$4.79 - $6.68 $6.13 Million - $8.55 Million
1,279,481 Added 180.28%
1,989,199 $12.1 Million
Q2 2021

Aug 16, 2021

BUY
$5.35 - $6.35 $3.8 Million - $4.51 Million
709,718 New
709,718 $4.19 Million

Others Institutions Holding CERS

About CERUS CORP


  • Ticker CERS
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Medical Devices
  • Shares Outstandng 177,090,000
  • Market Cap $280M
  • Description
  • Cerus Corporation operates as a biomedical products company. The company focuses on developing and commercializing the INTERCEPT Blood System to enhance blood safety. Its INTERCEPT Blood System, a proprietary technology for controlling biological replication that is designed to reduce blood-borne pathogens in donated blood components intended fo...
More about CERS
Track This Portfolio

Track Polar Capital Holdings PLC Portfolio

Follow Polar Capital Holdings PLC and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Polar Capital Holdings PLC, based on Form 13F filings with the SEC.

News

Stay updated on Polar Capital Holdings PLC with notifications on news.